Abstract
To understand the potential role of cyclooxygenase (COX) in normal and inflammatory human diseases, we characterized the expression of COX-1 and COX-2 in biopsies of osteoarthritis, atherosclerosis, and cancer. Tissues were prepared for immunohistochemistry by standard methods, and representative cases assayed via Western blot and quantitative RT-PCR. COX-2 was not detected in normal human tissues with few exceptions. Moderate to marked COX-2 was observed in the macula densa (MD) and thick ascending limb (TAL) in human fetal kidneys, but was not detected in neonatal and adult MD and TALs. Low level, constitutive COX-2 was detected in colonic epithelium, peribronchial glands, and pancreatic ductal epithelium. Low to moderate COX-2 was detected basally in the cortex, hippocampus, hypothalamus, and spinal cord, and in reproductive tissues during ovulation, implantation and labor. No COX-2 was detected in the existing vasculature in normal tissues, and was also not expressed throughout the ductus arteriosus. COX-2 was markedly induced in human tissues of osteoarthritis, atherosclerosis and cancer. COX-2 was prominently expressed in the synovium, fibrocartilage of osteophytes, and in the blood vessels in the osteoarthritic (OA) knee joint. COX-2 was also prominently detected in the macrophages/ foam cells in atherosclerotic plaques, and in the endothelium overlying and immediately adjacent to the fibrofatty lesion. Moderate-to intense COX-2 expression was consistently observed in the inflammatory cells, neoplastic lesions, and blood vessels in all epithelial-derived human cancers studied. In contrast, COX-1 was relatively ubiquitously observed in both normal and pathophysiological conditions. These data collectively imply COX-2 plays an important role in mediating a variety of inflammatory diseases, and imply COX-2 inhibitors may be effective in the prevention and/or treatment of OA, heart disease, and epithelial cancers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
G.N. Levy, Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer, FASEB J. 11:234 (1997).
H.R. Herschman, Prostaglandin synthase-2, Biochem. Biophys. Acta. 1299:125 (1996).
K. Seibert, Y. Zhang, K. Leahy et al., Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain, Proc. Natl. Acad. Sci. USA 91:12013 (1994).
R.N. DuBoise, R.S. Abramson, L. Crofford, R.A. Gupta, L.S. Simon et al., Cyclooxygenase in biology and disease, FASEB J. 12:1063 (1998).
M. Oshima, J.E. Dinchuck, S.L. Kargman, H. Oshima, B. Hancock, et al., Suppression of intestinal polyposis in APC delta 16 knockout mice by inhibition of cyclooxygenase-2 (COX-2), Cell 87:803 (1996).
C.C. Chan, S. Boyce, C. Brideau et al., Rofecoxib [Vioxx, MK-0966; 4-(4’-methylsulfonylphenyl)-3phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J. Pharmacol. Exp. Ther. 290:551 (1999).
L.S. Simon, F.L. Lanza, P.E. Lipsky et al., Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects, Arthritis Rheum. 41(9):1591 (1998).
A.T. Koki, K.M. Leahy, and J.L. Masferrer, Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy, Exp. Opin. Invest. Drugs 8(10):1623 (1999).
Renal paper
J.L. Masferrer, P.C. Isakson, and K. Seibert, Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agent that spare the gastrointestinal tract, Gastroeneterol. Clin. North Am. 25:363 (1996).
L.J. Marnett, Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer, Preventive Med. 24:103 (1995).
M.J. Reeves, P.A. Newcomb, A. Trentham-Dietz, B.E. Storer, and P.L. Remington, Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women, Cancer Epid. Biomark. Prey. 5:955 (1996).
M.J. Thun, M.M. Namboodiri, E.E. Calle, W.D. Flanders, and C.W. Heath, Aspirin use and risk of fatal cancer, Cancer Res. 53:1322 (1993).
R.E. Harris, K.K. Namboodiri, and W.B. Farrar, Nonsteroidal antiinflammatory drugs and breast cancer, Epidemiol. 5:138 (1996).
D.M. Schreinemachers, and R.B. Everson, Aspirin use and lung, colon, and breast cancer incidence in a prospective study, Epidemiol. 5:138 (1994).
D.C. Farrow, T.L. Vaughan, P.D. Hansten et al., Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer, Cancer Epid. Biom. & Prey. 7:97 (1998).
B.S. Reddy, Y. Hirose, R. Lubet, V. Steele, G. Kelloff, S. Paulson, K, Seibert, and C.V. Rao, Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis, Cancer Res. 60(2):293 (2000).
T. Kawamori, C.V. Rao, K. Seibert, and B.S. Reddy, Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis, Cancer Res. 58:409 (1998).
S.M. Fischer, H.H. Lo, G.B. Gordon et al., Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis, Molec. Carcinogenesis 25:231 (1999).
J.L. Masferrer, K.M. Leahy, A.T. Koki et al., Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res. (in press).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Koki, A. et al. (2002). Cyclooxygenase-2 In Human Pathological Disease. In: Honn, K.V., Marnett, L.J., Nigam, S., Dennis, E., Serhan, C. (eds) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 5. Advances in Experimental Medicine and Biology, vol 507. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0193-0_28
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0193-0_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4960-0
Online ISBN: 978-1-4615-0193-0
eBook Packages: Springer Book Archive